Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

ObjectiveIn the double-blind, phase III, placebo-controlled RUBY randomized clinical trial, dostarlimab plus carboplatin-paclitaxel significantly increased survival among patients with primary advanced or recurrent endometrial cancer (EC). We conducted a cost-effectiveness analysis of dostarlimab in...

Celý popis

Podrobná bibliografie
Hlavní autoři: Gengwei Huo, Ying Song, Wei Liu, Hua Guo, Peng Chen
Médium: Článek
Jazyk:English
Vydáno: Frontiers Media S.A. 2024-06-01
Edice:Frontiers in Pharmacology
Témata:
dostarlimab
endometrial cancer
Markov model
RUBY
cost-effectiveness
On-line přístup:https://www.frontiersin.org/articles/10.3389/fphar.2024.1391896/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1391896/full

Podobné jednotky